Search details
1.
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 783-794, 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-38381664
2.
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
N Engl J Med
; 390(9): 795-805, 2024 Feb 29.
Article
in English
| MEDLINE | ID: mdl-37962077
3.
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH.
N Engl J Med
; 389(11): 998-1008, 2023 Sep 14.
Article
in English
| MEDLINE | ID: mdl-37356033
4.
PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic-associated steatotic liver disease.
Hepatology
; 2024 Apr 23.
Article
in English
| MEDLINE | ID: mdl-38652636
5.
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis.
Hepatology
; 79(3): 674-689, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-37732990
6.
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Hepatology
; 2024 Mar 22.
Article
in English
| MEDLINE | ID: mdl-38506926
7.
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
N Engl J Med
; 385(17): 1559-1569, 2021 10 21.
Article
in English
| MEDLINE | ID: mdl-34670043
8.
Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
Gastroenterology
; 165(2): 463-472.e5, 2023 08.
Article
in English
| MEDLINE | ID: mdl-37127100
9.
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
Hepatology
; 77(1): 20-32, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-35686937
10.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology
; 78(6): 1966-1986, 2023 Dec 01.
Article
in English
| MEDLINE | ID: mdl-37363821
11.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology
; 78(2): 397-415, 2023 08 01.
Article
in English
| MEDLINE | ID: mdl-37386786
12.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Ann Hepatol
; 29(1): 101133, 2024.
Article
in English
| MEDLINE | ID: mdl-37364816
13.
Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease.
J Hepatol
; 78(4): 693-703, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36528237
14.
Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis.
J Hepatol
; 79(5): 1110-1120, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37517454
15.
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
J Hepatol
; 79(6): 1542-1556, 2023 12.
Article
in English
| MEDLINE | ID: mdl-37364790
16.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Clin Gastroenterol Hepatol
; 21(6): 1552-1560.e2, 2023 06.
Article
in English
| MEDLINE | ID: mdl-35934287
17.
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls.
Gastroenterology
; 163(6): 1630-1642.e3, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36150526
18.
Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis.
Am J Gastroenterol
; 118(2): 232-242, 2023 02 01.
Article
in English
| MEDLINE | ID: mdl-36729104
19.
Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.
Am J Gastroenterol
; 118(7): 1196-1203, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36621963
20.
Long-term outcomes and trends in liver transplantation for hereditary hemochromatosis in the United States.
Liver Transpl
; 29(1): 15-25, 2023 01 01.
Article
in English
| MEDLINE | ID: mdl-35770428